NASDAQ:ARCTArcturus Therapeutics Stock Price, Forecast & News

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARCT stock has increased by 203.7% and is now trading at $39.76. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcturus Therapeutics.

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Arcturus Therapeutics.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.08. The biotechnology company had revenue of $2.65 million for the quarter, compared to analyst estimates of $7.52 million. Arcturus Therapeutics had a negative net margin of 151.34% and a negative return on equity of 409.05%. View Arcturus Therapeutics' earnings history.

6 equities research analysts have issued 1-year price objectives for Arcturus Therapeutics' stock. Their forecasts range from $18.00 to $62.00. On average, they expect Arcturus Therapeutics' share price to reach $29.50 in the next twelve months. This suggests that the stock has a possible downside of 25.8%. View analysts' price targets for Arcturus Therapeutics.

Media coverage about ARCT stock has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a news impact score of 1.7 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View the latest news aboutArcturus Therapeutics.

Arcturus Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 335,000 shares, an increase of 58.3% from the April 15th total of 211,600 shares. Based on an average daily volume of 218,700 shares, the short-interest ratio is presently 1.5 days. Approximately 3.8% of the company's stock are sold short. View Arcturus Therapeutics' Current Options Chain.

Some companies that are related to Arcturus Therapeutics include PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Arena Pharmaceuticals (ARNA), Uniqure (QURE), Axsome Therapeutics (AXSM), Alkermes (ALKS), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Insmed (INSM), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Karuna Therapeutics (KRTX) and Ra Pharmaceuticals (RARX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Opko Health (OPK), Crispr Therapeutics (CRSP), Pfizer (PFE), Sanofi (SNY), Abbott Laboratories (ABT), Intel (INTC) and Ocular Therapeutix (OCUL).

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Dfpg Investments LLC (2.09%), Cormorant Asset Management LP (1.32%), Nikko Asset Management Americas Inc. (1.33%), Sumitomo Mitsui Trust Holdings Inc. (1.33%), Nikko Asset Management Americas Inc. (1.32%) and Morgan Stanley (1.02%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View institutional ownership trends for Arcturus Therapeutics.

ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, DAFNA Capital Management LLC, Two Sigma Investments LP, JPMorgan Chase & Co., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., and Creative Planning. View insider buying and selling activity for Arcturus Therapeutics.

ARCT stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Morgan Stanley, Morgan Stanley, Engineers Gate Manager LP, Jane Street Group LLC, Acadian Asset Management LLC, Wells Fargo & Company MN, and Trexquant Investment LP. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet, and Peter C Farrell. View insider buying and selling activity for Arcturus Therapeutics.

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARCT stock can currently be purchased for approximately $39.76.

Arcturus Therapeutics has a market capitalization of $790.83 million and generates $20.79 million in revenue each year. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.

The official website for Arcturus Therapeutics is www.arcturusrx.com.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]